978P Pertuzumab plus trastuzumab (P+T) in patients (pts) with lung cancer (LC) with ERBB2 mutation (mut) or amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study
| Autor: | Ganti, A.K., Rothe, M., Mangat, P.K., Garrett-Mayer, E., Dib, E.G., Duvivier, H., Ahn, E., Behl, D., Borghaei, H., Balmanoukian, A.S., Gaba, A., Li, R., Osei-Boateng, K., Thota, R., O'Lone, R., Grantham, G.N., Halabi, S., Schilsky, R.L. |
|---|---|
| Zdroj: | In Annals of Oncology September 2022 33 Supplement 7:S997-S998 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|